Jaguar Animal Health, Inc. (NASDAQ:JAGX) Short Interest Update

Jaguar Animal Health, Inc. (NASDAQ:JAGX) was the recipient of a significant growth in short interest during the month of January. As of January 15th, there was short interest totaling 552,389 shares, a growth of 99.4% from the December 31st total of 277,020 shares. Based on an average daily volume of 3,207,496 shares, the short-interest ratio is currently 0.2 days. Approximately 16.0% of the company’s shares are short sold. Approximately 16.0% of the company’s shares are short sold. Based on an average daily volume of 3,207,496 shares, the short-interest ratio is currently 0.2 days.

Jaguar Animal Health Price Performance

NASDAQ JAGX traded down $0.02 during trading hours on Friday, reaching $0.67. The stock had a trading volume of 339,406 shares, compared to its average volume of 10,774,265. The company has a debt-to-equity ratio of 4.08, a current ratio of 0.81 and a quick ratio of 0.52. Jaguar Animal Health has a 52-week low of $0.64 and a 52-week high of $25.75. The stock has a fifty day moving average of $1.06 and a 200 day moving average of $1.68.

Jaguar Animal Health (NASDAQ:JAGX) last posted its earnings results on Friday, November 14th. The biotechnology company reported ($6.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.08) by ($1.20). The firm had revenue of $3.08 million during the quarter, compared to analyst estimates of $3.73 million. Jaguar Animal Health had a negative net margin of 341.90% and a negative return on equity of 1,194.94%. Research analysts forecast that Jaguar Animal Health will post -0.8 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on JAGX. Wall Street Zen cut shares of Jaguar Animal Health to a “strong sell” rating in a research report on Friday, January 23rd. Weiss Ratings restated a “sell (e+)” rating on shares of Jaguar Animal Health in a report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Jaguar Animal Health currently has an average rating of “Hold” and a consensus price target of $60.00.

Jaguar Animal Health Company Profile

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.